The prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis

Sohail Akhtar 1*, Jamal Abdul Nasir 1 and Andrew Hinde 2

Abstract

Background: Hepatitis C virus infection is the most commonly reported bloodborne infection in Pakistan. Frequent blood transfusions in β-thalassemia patients expose them to a high risk of HCV infection. The purpose of this paper is to summarise the current data on the prevalence of HCV infection in β-thalassemia patients in Pakistan by using a systematic review and meta-analysis.

Methods: PubMed, EMBASE, Web of Sciences, the Cochrane Library, Directory of Open Access Journal and local databases were systematically searched for studies published between January 1st, 1995 and May 31st, 2019. Meta-analysis was performed using the DerSimonian and Laird random-effects models with inverse variance weighting. The presence of publication bias was tested by Egger test, and the methodological quality of each included article was evaluated by the STROBE.

Results: We identified a total of 229 potential studies, of which 27 studies were finally considered in the meta-analysis. The pooled prevalence of HCV in β-thalassemia patients in Pakistan was 36.21% (95% CI: 28.98–43.75%) based on 5789 β-thalassemia patients, but there was considerable heterogeneity. Meta-analysis estimated the HCV prevalence among the β-thalassemia patients at 45.98% (95% CI: 38.15–53.90%) in Punjab, 31.81% (95% CI: 20.27–44.59%) in Sindh, and 28.04% (95% CI: 13.58–45.26%) in Khyber Pakhtunkhwa. Meta-regression analysis showed that geographical location was a key source of heterogeneity.

Conclusions: The pooled prevalence of HCV in β-thalassemia patients in Pakistan was more than one in three, and higher than in neighbouring countries. It varies regionally within the country. With the use of standard prevention procedures during blood transfusion, the risk of HCV transmission in β-thalassemia patients could be controlled and the prevalence of HCV in β-thalassemia patients reduced.

Keywords: Prevalence, HCV, β-Thalassemia, Pakistan, Systematic review, Meta-analysis

Background

The β-thalassemias are among the most common genetic diseases and affect millions of children throughout the world [1]. Around 1.5% (80–90 million people) of the worldwide population are carriers for β-thalassemia, with 50,000–60,000 new β-thalassemia cases being born each year [2]. β-thalassemia is most prevalent in the populations of Asia, the Indian subcontinent, the Mediterranean countries, Africa and the Middle East [3–5]. In Pakistan, β-thalassemia is one of the commonest...
inherited disorders, with a carrier frequency of 5 to 7% of the Pakistani population [2]. β-thalassemia patients are now surviving to older ages due to the availability of blood transfusion and iron chelation. There are around 100,000 patients registered currently but the burden of disease is increasing, with 5000 to 9000 children born with the disorder annually [6].

Bloodborne infections are the second commonest reason of death in β-thalassemia patients in Pakistan [2]. Regular blood transfusions in β-thalassemia patients expose them to a higher risk of contracting HCV viral infection, especially if adequate viral screening of blood donors has not been undertaken. The infection risk in β-thalassemia patients acts as a marker for the risk of transfusion-transmitted infections in the general population as their exposure to blood transfusions is high. If the infection rate is low in β-thalassemia patients it implies that the risk for the general population will be minimal.

Hepatitis C infection is one of the most common bloodborne infections. More than 10 million individuals are living with HCV infection in Pakistan, and hence vulnerable to high morbidity and mortality [7]. Pakistan is a developing country: according to the Human Development Index of the United Nations, it stands in 150th position out of 189 countries and territories [8]. The health standard in Pakistan is well below the international standards to which all countries aspire. Therefore, contaminated blood transfusion is still a main risk factor for the spread of HCV. This is due to the lack of screening and the widespread use of paid blood donors [9]. Several studies have been published on the prevalence of HCV in β-thalassemia patients in Pakistan and there is considerable variation in the prevalence reported in the individually published studies. The purpose of this study is to investigate the pooled prevalence based on the available published studies conducted on the prevalence of HCV infection in β-thalassemia patients and to describe its associated risk factors in Pakistan. To our knowledge, this is the first systematic review and meta-analysis to investigate the pooled prevalence of HCV infection in β-thalassemia patients in the country.

**Methods**

**Search strategy**

A systematic literature search on PubMed, EMBASE, the Cochrane Library, Web of Sciences, Directory of Open Access Journal and Pakistani Journals Online websites was conducted by two authors (J.A.N. and S.A.) to find studies performed on the prevalence of HCV infection in β-thalassemia patients and published from January 1st, 1995 to May 31st 2019. Using MeSH headings, we searched for, the terms “prevalence”, “epidemiology”, “seroprevalence”, “hepatitis C Virus”, “HCV”, “hepacivirus”, “hep C,” “thalassemia”, “β-thalassemia”, “thalassemia major”, “multitransfused blood transfusion”, “patients”, “Pakistan”, and “Pakistani”, as well as variations thereof. The results were defined using the Preferred Reporting Items for Systematic and Meta-analyses (PRISMA) statement (Table 1) [10], and the PRISMA 2009 checklist is attached in supplementary file S1.

**Inclusion and exclusion criteria**

Studies were included in this study if: (1) they were published in peer-reviewed journals; (2) they were conducted in Pakistan; (3) they reported on the prevalence HCV in thalassemia patients; (4) they were published in the English language.

Studies were excluded if: (1) they were in languages other than English; (2) they were case series, reviews, letters, and editorials or commentaries; (3) they did not allow the calculation of the prevalence of HCV; (4) they were duplicates (using the same data), in which case the more recently published version only was considered; (5) they related to the Pakistani community living outside Pakistan.

**Data extraction**

After choosing the relevant articles, two reviewers (J.A.N. and S.A.) independently screened the titles and abstracts to identify articles for full-text read. The data was then extracted using a standardised data extraction template of Microsoft Office Excel 2013. Information extracted included: surname of first author, year of study, year of publication, geographic region (province), gender, study design, study setting (rural, urban or both), sample size and average age of β-thalassemia patients. Any disagreement regarding the extracted information was resolved by discussion and mutual consensus.

**Evaluating the quality of the included studies**

Two authors (J.A.N. and S.A.) also independently judged the methodological quality of each included study using Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [11]. Any disagreement on the quality assessment check list was resolved by discussion and consensus. We categorized the quality of each included study as ‘good’ if its scored at least 70% of the points available, ‘medium’ if it scored 50–69%, and ‘poor’ if its scored less than 50%.

**Statistical analysis**

Statistical analyses were conducted by the software R, version 3.5.3 [12], using two packages: ‘meta’ and ‘metafor’. Random effects (DerSimonian-Laird) models were used to make point estimates and their 95% confidence intervals (95% CIs), as well as to estimate the pooled prevalence of HCV among the β-thalassemia patients. A
Table 1 Description and list of characteristics of the included studies

| Author | Year | Study Design | Sample size | Cases | Prevalence (%) | Setting | Province | Sex | Working Year | % Female | % Male | Average Age | Test | Quality |
|--------|------|--------------|-------------|-------|----------------|---------|----------|-----|--------------|----------|--------|-------------|------|---------|
| Bhatti et al. [18] | 1995 | NA | 35 | 21 | 60.00 | Urban | Khyber Pakhtunkhwa | Both | NA | 14.28 | 85.71 | 6.5 | ELISA | Medium |
| Muhammad et al. [19] | 2003 | Cross-sectional | 80 | 29 | 36.25 | Urban | Khyber Pakhtunkhwa | Both | Jul. 1999 to Mar. 2001 | NA | NA | 7.5 | ELISA | Medium |
| Shah et al. [20] | 2005 | Cross-sectional | 250 | 142 | 56.80 | Urban | Khyber Pakhtunkhwa | Both | Jan. 2000 to Jan. 2001 | 72.00 | 28 | 10 | ELISA | Medium |
| Hussain [21] | 2008 | Cross-sectional | 180 | 75 | 41.67 | Urban | Khyber Pakhtunkhwa | Both | Jan. 2002 to Dec. 2003 | NA | NA | 6.8 | ELISA | Good |
| Ali et al. [22] | 2011 | NA | 167 | 26 | 15.57 | Urban | Khyber Pakhtunkhwa | Both | NA | 62.28 | 36.7 | NA | RNA | Medium |
| Khattak et al. [23] | 2013 | NA | 170 | 37 | 21.67 | Urban | Khyber Pakhtunkhwa | Both | NA | 55.29 | 44.71 | 10 | ELISA | Medium |
| Khan et al. [24] | 2015 | Cross-sectional | 180 | 14 | 7.77 | Urban | Khyber Pakhtunkhwa | Both | Jun. 2013 to Dec. 2012 | 38.89 | 61.11 | NA | NA | Medium |
| Shah et al. [25] | 2018 | NA | 324 | 18 | 5.56 | Urban | Khyber Pakhtunkhwa | Both | Oct. 2013 to Mar. 2014 | 34.50 | 60.23 | 15.5 | RNA | Medium |
| Younus et al. [26] | 2004 | Cross-sectional | 75 | 32 | 42.00 | Urban | Punjab | Both | Jul. to Sep. 2003 | 64.00 | 36 | 6.5 | ELISA | Good |
| Iqbal et al. [27] | 2010 | NA | 141 | 50 | 35.46 | Urban | Punjab | Both | Sep. 2008 to Aug. 2009 | 58.20 | 41.8 | 8 | ELISA | Medium |
| Chin et al. [28] | 2011 | Cross-sectional | 300 | 195 | 65.00 | Urban | Punjab | Both | NA | 34.33 | 65.67 | 10 | NA | Medium |
| Iqbal et al. [29] | 2013 | Cross-sectional | 95 | 40 | 42.11 | Urban | Punjab | Both | Oct. 2009 Apr. 2010 | 60.00 | 40 | 9.2 | ELISA | Medium |
| Din et al. [30] | 2014 | NA | 95 | 45 | 47.00 | Both | Punjab | Both | Jul. 2017 to Sept. 2017 | 56.84 | 53.68 | 7 | ELISA | Good |
| Nazir et al. [31] | 2014 | NA | 200 | 82 | 41.00 | Urban | Punjab | Both | Jan. 2013 to May 2013 | 12.00 | 88 | 8.5 | ELISA | Medium |
| Saeed et al. [32] | 2015 | Cross-sectional | 262 | 146 | 55.73 | Urban | Punjab | Both | Nov. 2011 to Apr. 2012 | 40.07 | 59.92 | 9.26 | ELISA | Medium |
| Sheikh et al. [33] | 2015 | Cross-sectional | 145 | 99 | 68.27 | Urban | Punjab | Both | Jan. 2009 to Dec. 2009 | 63.45 | 36.55 | 9 | ELISA | Medium |
| Khan et al. [34] | 2017 | Cross-sectional | 470 | 216 | 45.95 | Urban | Punjab | Both | Mar. 2014 to Sep. 2014 | 65.96 | 34.04 | 4.8 | ELISA | Medium |
| Rashid et al. [35] | 2017 | Cross-sectional | 130 | 27 | 20.76 | Urban | Punjab | Both | Jan. 2014 to Jun. 2014 | 60.00 | 40 | 9.7 | ELISA | Medium |
| Raza et al. [36] | 2018 | Cross-sectional | 200 | 82 | 41.00 | Urban | Punjab | Both | Jan. 2015 to Dec. 2016 | 43.00 | 57 | 10.11 | ELISA | Good |
| Mujeeb et al. [37] | 1997 | NA | 91 | 46 | 50.54 | Urban | Sindh | Both | NA | 39.56 | 60.43 | 13 | NA | Medium |
| Akhtar et al. [38] | 2002 | Cross-sectional | 341 | 70 | 20.50 | Urban | Sindh | Both | Jun-91 | NA | NA | 5 | RNA | Good |
| Akhtar et al. [39] | 2004 | NA | 86 | 38 | 44.20 | Urban | Sindh | Both | NA | 31.40 | 67.44 | 12 | ELISA | Medium |
| Riaz et al. [40] | 2011 | Cross-sectional | 79 | 34 | 43.00 | Urban | Sindh | Both | Jul. 2009 to Sep. 2009 | 41.77 | 58.23 | 12 | ELISA | Medium |
| Ansari et al. [41] | 2012 | Cross-sectional | 160 | 21 | 13.10 | Urban | Sindh | Both | Jan. 2010 to Dec. 2010 | 49.38 | 50.63 | 8.5 | ELISA | Medium |
| Sultan et al. [42] | 2016 | Cross-sectional | 100 | 27 | 27.00 | Urban | Sindh | Both | Jun. 2011 to Jun. 2014 | 54.00 | 46 | 15 | ELISA | Good |
| Burki et al. [43] | 2005 | NA | 180 | 75 | 41.67 | Urban | Punjab + Khyber Pakhtunkhwa | Both | Jan. 2002 to Dec. 2003 | NA | NA | 6 | ELISA | Medium |
| Kiani et al. [44] | 2016 | Cross-sectional | 1253 | 273 | 21.71 | Urban | Punjab + Sindh | Both | Jul. 2015 to Dec. 2015 | 46.21 | 53.79 | 10.1 | NA | Medium |
process for combining prevalence in the meta-analysis of multiple studies was used and the results presented in a forest plot. The Random effect models are more conservative than fixed effect models, and have better statistical properties in the presence of heterogeneity, as the random effects model allows both within-study and between-study variances [13, 14]. The Freeman–Tukey Double Arcsine transformation was used to stabilise the variance prior to the calculation of the pooled estimates [15]. Heterogeneity among the eligible articles was investigated with the $I^2$ index [16]. For the $I^2$-index, values of 75, 50, and 25% were considered high, moderate, and low levels of heterogeneity, respectively. To determine the possible reasons for substantial heterogeneity, univariate meta-regression and subgroup analyses were conducted by geographical location, sample size, year of study, year of publication, gender and average age of the β-thalassemia patients. The presence of publication bias was evaluated by visually inspecting a funnel plot and test using Egger test [17], with $p$-value less than 0.05 indicating significant publication bias.

**Results**

**Literature search**

Initially, 229 potential studies were identified. Of these, 77 were duplicates and were removed. We screened the titles and abstracts, and eliminated 109 irrelevant studies from the meta-analysis. As a result, only 43 articles were considered for full text review. Sixteen studies were eliminated after full text review: studies with no quantitative measures of hepatitis C virus in β-thalassemia patients; studies that were not conducted in Pakistan; studies that provided combined HCV and hepatitis B virus prevalence; studies based on duplicated data sets or that did not meet the eligibility criteria or that failed to include relevant indicators. In the end, 27 studies fulfilled the inclusion criteria and data were extracted. Figure 1 shows the study flow diagram (PRISMA) for the selection process [10].

**Characteristics of the included studies**

The characteristics of the selected articles are summarised in Table 1. A cross-sectional research design was used in 17 studies, whereas ten studies did not clearly specify the research design. The articles were published between January 1995 and December 2018, while the period of participant inclusion was from June 1991 to September 2017. Three provinces of Pakistan were represented in the included studies: eight were conducted in Khyber Pakhtunkhwa [18–25], 11 were conducted in Punjab [26–36] and six were conducted in Sindh [37–42]. One study was conducted both in Punjab and Khyber Pakhtunkhwa [43] while one was conducted

---

**Fig. 1 PRISMA 2009 flow diagram [10] explaining the number of included and excluded articles in the meta-analysis on the prevalence of HCV in β-thalassemia patients in Pakistan**
in Punjab and Sindh [44]. Most of the included studies (20 out of 27) reported (the) HCV prevalence based on the results of the ELISA (enzyme-linked immunosorbent assay) test [17–20, 22, 25, 26, 28–35, 40–43]. Only three studies reported the confirmation of HCV infection by RNA test [21, 24, 39]. Four studies did not explicitly mention the diagnostic methods they used for HCV antibody reactivity testing [23, 27, 36, 38]. The sex of the patients was reported in 23 studies. The proportion of females ranged from 28.0 to 88.0%. The average age of patients varied from 4 years [34] to 15.5 years [25]. After reviewing the methodological quality of the studies, 6 were deemed to be of good quality, 21 of medium quality, and no article was found with poor quality. Sample size varied among studies with the smallest having a total of 35 patients [17] and the largest 1253 patients [35].

Prevalence of HCV in β-thalassemia patients

Table 2 shows the summary of statistical analyses of the prevalence of the HCV in β-thalassemia patients in Pakistan. The overall prevalence of HCV infection in β-thalassemia patients was 36.21% (95% CI: 28.98–43.75%, $I^2 = 97.0%$; 27 studies), based on a pooled sample of 5789. A forest plot of HCV prevalence in the β-thalassemia patients in the three provinces of Pakistan is presented in Fig. 2. Visual inspection of the funnel plot (Fig. 3) revealed some evidence of publication bias, but it was insignificant based on Egger test ($p = 0.1506$). Table 2 also presents the pooled prevalence of HCV in β-thalassemia patients for subgroups. The pooled subgroup prevalence stratified by geographical location (province) revealed that the prevalence of HCV in β-thalassemia patients was highest in Punjab at 45.98% (95% CI: 38.15–53.90%, $I^2 = 92.3%$, based on 11 studies), compared with 31.81% (95% CI: 20.27–44.59%, $I^2 = 92.8%$; based on 6 studies) in Sindh and 28.04% (95% CI: 13.58–45.26%, $I^2 = 97.6%$; based on 8 studies) in Khyber Pakhtunkhwa. There was no significant difference in the prevalence of HCV between male (34.71% (95% CI: 23.32–47.04%)) and female (32.31% (95% CI: 20.17–45.75%)) β-thalassemia patients. The prevalence of HCV in β-thalassemia patients increased with age: the prevalence among those below 10 years of age was 33.87% (95% CI: 18.93–50.62%, $I^2 = 96.2%$; 9 studies) while for those above 10 years it was 51.51% (95% CI: 34.52–68.34%, $I^2 = 96.2%$; 9 studies). There was no publication bias in any subgroup.

The results of the univariate meta-regression analysis of the prevalence of HCV in β-thalassemia patients are presented in Table 3. The analysis shows that only geographical region (province) had a significant effect on the prevalence of HCV in β-thalassemia patients with a $p$-value < 0.1, while year of publication, year of study, sample size, proportion of males, average age of thalassemia patients had no significant effect on the observed HCV prevalence in β-thalassemia patients.

Discussion

The aim of this study was to summarise the available literature on the prevalence of hepatitis C virus infection in β-thalassemia patients and its correlated risk factors in Pakistan. The result of this meta-analysis showed that

| Studies | Sample | Cases | Prevalence % (95% confidence interval) | $I^2$ | Heterogeneity | $p$ value for $Egger's$ test | $p$ value for difference |
|---------|--------|-------|----------------------------------------|------|---------------|----------------------------|------------------------|
| Prevalence of HCV in β-thalassemia patients | 27 | 5789 | 1960 | 36.2 (28.98–43.75) | 0.970 | < 0.001 | 0.1506 |
| By sex | | | | | | | |
| Male | 12 | 1894 | 592 | 34.71 (23.32–47.04) | 0.963 | < 0.0001 | 0.2923 |
| Female | 12 | 1316 | 364 | 32.31 (20.17–45.75) | 0.952 | < 0.0001 | 0.2304 |
| By age | | | | | | | |
| Less than 10 years | 9 | 970 | 386 | 33.87 (18.93–50.62) | 0.962 | 0.0915 | 0.4417 |
| 10 years or above | 9 | 509 | 243 | 51.51 (34.52–68.34) | 0.932 | < 0.001 | 0.1705 |
| By province | | | | | | | |
| Punjab | 11 | 2113 | 1014 | 45.98 (38.15–53.90) | 0.923 | < 0.001 | 0.1496 |
| Sindh | 6 | 857 | 236 | 31.81 (20.27–44.59) | 0.928 | < 0.001 | 0.0922 |
| Khyber Pakhtunkhwa | 8 | 1386 | 362 | 28.04 (13.58–45.26) | 0.976 | < 0.001 | 0.3754 |
| By period | | | | | | | |
| 1995–2004 | 6 | 708 | 223 | 41.27 (28.15–55.03) | 0.913 | < 0.0001 | 0.0050 |
| 2005–2014 | 12 | 2017 | 822 | 38.03 (28.13–48.45) | 0.956 | < 0.001 | 0.2211 |
| 2015–2018 | 9 | 3064 | 902 | 30.66 (18.06–44.91) | 0.983 | < 0.001 | 0.5755 |
| Study                  | Events | Total | Events per 100 observations | Events | 95%-CI  | Weight |
|------------------------|--------|-------|-----------------------------|--------|---------|--------|
| Bhatti et al. 1995     | 21     | 35    |                             | 60.00  | [42.11; 76.13] | 3.3%   |
| Mujeeb et al. 1997     | 46     | 91    |                             | 50.55  | [39.86; 61.20] | 3.6%   |
| Akhtar et al. 2002     | 70     | 341   |                             | 20.53  | [16.37; 25.21] | 3.8%   |
| Muhammad et al. 2003   | 29     | 80    |                             | 36.25  | [25.79; 47.76] | 3.6%   |
| Akhtar et al. 2004     | 38     | 86    |                             | 44.19  | [33.48; 55.30] | 3.6%   |
| Younus et al. 2004     | 32     | 75    |                             | 42.67  | [31.31; 54.62] | 3.6%   |
| Burki et al. 2005      | 75     | 180   |                             | 41.67  | [34.38; 49.23] | 3.7%   |
| Shah et al. 2005       | 142    | 250   |                             | 56.80  | [50.41; 63.03] | 3.8%   |
| Hussain 2008           | 75     | 180   |                             | 41.67  | [34.38; 49.23] | 3.7%   |
| Iqbal et al. 2010      | 50     | 141   |                             | 35.46  | [27.59; 43.95] | 3.7%   |
| Riaz et al. 2011       | 34     | 79    |                             | 43.04  | [31.94; 54.67] | 3.6%   |
| Ain et al. 2011        | 195    | 300   |                             | 65.00  | [59.31; 70.39] | 3.8%   |
| Ali et al. 2011        | 26     | 167   |                             | 15.57  | [10.43; 21.97] | 3.7%   |
| Ansari et al. 2012     | 21     | 160   |                             | 13.12  | [8.31; 19.36]  | 3.7%   |
| Iqbal et al. 2013      | 40     | 95    |                             | 42.11  | [32.04; 52.67] | 3.6%   |
| Khattak et al. 2013    | 37     | 170   |                             | 21.76  | [15.81; 28.73] | 3.7%   |
| Din et al. 2014        | 45     | 95    |                             | 47.37  | [37.03; 57.88] | 3.6%   |
| Nazir et al. 2014      | 82     | 200   |                             | 41.00  | [34.11; 48.16] | 3.8%   |
| Khan et al. 2015       | 14     | 180   |                             | 7.78   | [4.32; 12.71]  | 3.7%   |
| Saeed et al. 2015      | 146    | 262   |                             | 55.73  | [49.48; 61.84] | 3.8%   |
| Sheikh et al. 2015     | 99     | 145   |                             | 68.28  | [60.04; 75.75] | 3.7%   |
| Kiani et al. 2016      | 273    | 1253  |                             | 21.79  | [19.53; 24.18] | 3.9%   |
| Sultan et al. 2016     | 27     | 100   |                             | 27.00  | [18.61; 36.80] | 3.6%   |
| Khan et al. 2017       | 216    | 470   |                             | 45.96  | [41.38; 50.58] | 3.8%   |
| Rashid et al. 2017     | 27     | 130   |                             | 20.77  | [14.16; 28.76] | 3.7%   |
| Shah et al. 2018       | 18     | 324   |                             | 5.56   | [3.33; 8.64]   | 3.8%   |
| Raza et al. 2018       | 82     | 200   |                             | 41.00  | [34.11; 48.16] | 3.8%   |

**Random effects model** 5789  
**Prediction interval** 36.21 [28.98; 43.75] 100.0%  
[4.90; 76.52]  

Fig. 2 Forest plot of the prevalence of HCV infection among in β-thalassemia patients in Pakistan

| Study                  | Standard Error | Freeman-Tukey Double Arcsine Transformed Proportion |
|------------------------|----------------|-----------------------------------------------|
|                       |                | 0.00                                          |
|                       |                | 0.04                                          |
|                       |                | 0.08                                          |
|                       |                | 0.4                                           |
|                       |                | 0.6                                           |
|                       |                | 0.8                                           |
|                       |                | 1.0                                           |

Fig. 3 Funnel plot of the prevalence of HCV infection in β-thalassemia patients in Pakistan
the pooled prevalence based on 27 studies was 36.21%. More than one in every three \( \beta \)-thalassemia patients in Pakistan have already been exposed to HCV infection. The pooled prevalence of HCV in \( \beta \)-thalassemia patients, as showed by this study is six times higher (36.21%) than in the general Pakistani population which is 6.2% [45]. In Pakistan, many patients with \( \beta \)-thalassemia have limited access to regular and safe blood transfusions. Possible reasons for this are the lack of altruistic voluntary blood donors and the inadequate testing of blood donations for HCV. Many blood transfusion centers and hospitals have inadequate resources and kits for screening blood donations [5]. Pakistan is a low resource country; the pooled prevalence of HCV in \( \beta \)-thalassemia patients in Pakistan is higher than that in Iran [46] (19%) or Bangladesh [47] (14.7%). The findings of this study should act as a major safety alert for decision and policy-makers in the Pakistani health sector.

Our data on HCV infection prevalence among the \( \beta \)-thalassemia patients covers all provinces of Pakistan except Baluchistan and Gilgit-Baltistan. Our results showed that the prevalence of HCV infection in \( \beta \)-thalassemia patients was higher in Punjab (45.98%) than in Sindh (31.81%) and Khyber Pakhtunkhwa (28.04%).

In this paper, we observed that the prevalence of HCV in \( \beta \)-thalassemia patients rises with age, increasing from 33.87% in the under 10 years age group to 51.51% in the 10 years or above age group. This effect was not statistically significant at conventional levels. We believe that age is acting as a proxy for other effects. Age is associated with cumulative exposure to blood transfusions over a life time and it is the number of blood transfusions which is associated with increased risk of HCV infection. Unfortunately, we do not have data on the number of blood transfusion patients had received. Conversely, one could look at this more positively and suggest that the frequency of testing for HCV positive blood donations has improved and hence younger patients have a lower infection rate than their older fellow patients did when they were the same age, due to safer blood donations.

Meta-regression analyses showed that there was no significant change in the prevalence of HCV in \( \beta \)-thalassemia patients over the past three decades (with both years of publication and year of study (data collection).

To our knowledge, this is the first systematic review and meta-analysis to compile current data on the prevalence of HCV infection among \( \beta \)-thalassemia patients in Pakistan. The main strengths of this study are the use of a comprehensive and a predefined literature search strategy, and the involvement of two independent reviewers in the whole review process and data extraction. No publication bias was found within our analyses which suggests that we are unlikely to have missed any potential studies that could change the results of this meta-analysis. Furthermore, the methodological quality of all included articles had a low risk of bias. As showed by meta-regression analysis, the methodological quality of the studies had no influence on pooled prevalence estimates. Three provinces of Pakistan were covered in the investigation of HCV infection prevalence in \( \beta \)-thalassemia patients. On the other hand, the findings of this study have some limitations. Firstly, the meta-regression analysis was only based on bivariate analysis. We planned to use a multivariate meta-regression model by considering all the factors simultaneously, however, it was not possible to use multivariate meta-regression analysis due to the small number of studies. A multivariate meta-regression analysis requires at least ten studies per factor to estimate the meta-regression coefficients.

| Covariate                         | Category        | Number of Studies | Meta-regression Coefficient (%) | p-value | Variance explained \( R^2 \) (%) |
|----------------------------------|-----------------|-------------------|---------------------------------|---------|-----------------------------|
| Geographical region (Province)   | Khyber Pakhtunkhwa | 8                 | 1                               | 1       | 26.97                       |
|                                  | Punjab          | 11                | 0.1873                          | 0.0306  |                             |
|                                  | Sindh           | 6                 | 0.0447                          | 0.6582  |                             |
| Year of publication              |                 | 27                | –0.0098                         | 0.1176  | 1.33                        |
| Year of study                    |                 | 21                | –0.0076                         | 0.3058  | 0.00                        |
| Sample size                      | < 100           | 8                 | 1                               | 2.92    |                             |
|                                  | >= 100          | 19                | –0.1329                         | 0.1187  |                             |
| Proportion of males              |                 | 23                | –0.0003                         | 0.9189  | 0.00                        |
| Average age of patients          |                 | 25                | –0.0058                         | 0.6598  | 3.41                        |
| Sample size, continuous          |                 | 27                | –0.0098                         | 0.1176  | 1.33                        |
efficiently. Second, and as is common in meta-analyses, the study estimates revealed substantial heterogeneity between the included studies, which may be due to the other sources of variation which may have been missed in our analysis, such as the number of blood transfusions, some genetic factors, and type of β-thalassemia; but we were unable to investigate these factors due to lack of data.

Conclusions
The overall prevalence of HCV in β-thalassemia patients in Pakistan was 36.21%, but varied from province to province. The prevalence is higher than in neighboring countries such as Iran and Bangladesh. Pakistan is a developing country and lacking in resources for appropriate blood screening facilities in thalassemia centers and hospitals. Lack of robust policies on transfusion safety as well as appropriate and rigorous monitoring of blood banks to ensure compliance with policies perpetuate the risk of transfusion transmitted infection with HCV. National and regional health programs should mandate and monitor the screening procedures so as to reduce the risk of transfusion transmitted infections such as HCV in the general population in β-thalassemia patients.

Abbreviations
CI: 95% confidence interval; ELISA: Enzyme-Linked Immunosorbent Assay; HCV: Hepatitis C virus; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RNA: Ribonucleic Acid

Acknowledgements
Thanks Dr. Farrukh Shah for the initial comments on the paper and for editing the final draft.

Authors' contributions
SA and JAN conceived, designed the review and did the data collection for the study. The manuscript was drafted by SA and JAN. AH reviewed the manuscript originally submitted and revised it following the reviewer’s comments. SA and AH checked the final analysis and revised the manuscript. The authors read and approved the final manuscript.

Funding
No funding was received for this study.

Availability of data and materials
All relevant data is included within the manuscript file.

Ethics approval and consent to participate
Not applicable here, as this is systematic review and meta-analysis.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Statistics, Government College University, Lahore, Katchery Road, Lahore, Pakistan. 2Southampton Statistical Sciences Research Institute, University of Southampton, Southampton, UK.

References
1. World Health Organization (WHO), (2017). Available online at: https://www.who.int/genomics/public/geneticdiseases/en/index2.html, accessed on 15, July 2019.
2. Galanello R, Origa R. Beta-thalassemia. Orphanet j rare dis. 2010;5:11.
3. Kountouris P, Lederer CW, Fanis P, et al. thalGenes: an interactive database for haemoglobin variations and epidemiology. PLoS one. 2014;9:e103820.
4. Ladis V, Karagiorga-Lagana M, Tsatra J, et al. Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation. Eur J Haematol. 2013;90:313–22.
5. Shah, Farrukh T, Farzana Sayani, Sara Trompeter, Emma Drasar, and Antonio Piga, “Challenges of blood transfusions in β-thalassemia.” Blood reviews. 2019;37:100588.
6. The Thalassemia alert! Desperate measures (2014). https://tribune.com.pk/story/664301/thalassemia-alert-desperate-measures/ Assessed on 14 May 2019.
7. Hamid S, et al. PSG consensus statement on management of hepatitis C virus infection. J Pak Med Assoc. 2004;54:146–9.
8. United Nations Development Program. Human Development Report (2018). http://www.pk.undp.org/content/pakistan/en/home/blog/2018/human-development-in-pakistan.html Assessed 20 May 2019.
9. Luby S, Khanani ZM, et al. Evaluation of blood bank practices in Karachi, Pakistan, and the government’s response. Health Policy Plan. 2000;15:217–22.
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
11. National Heart, Lung and blood institute. Quality assessment tool for observational and cross-sectional studies. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed on 1 October 2019).
12. Team RC. R: a language and environment for statistical computing. (2013).
13. Chen H, Manning AK, Dupuis J. A method of moments estimator for random effect multivariate meta-analysis. Biomarkers. 2012;68(4):1278–84.
14. Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: a comparison between DerSimonian-Laird and restricted maximum likelihood. Stat Methods Med Res. 2012;21:657–9.
15. Barendregt JJ, Doi SA, Lee YY, Norman RE, et al. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–8.
16. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Vol. 4 (John Wiley & Sons, 2011).
17. Higgins JP. Thompson SG quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
18. Bhatti FA, Amin M, Saleem M. Prevalence of antibody to hepatitis C virus in Pakistani Thalassaemics by particle agglutination test utilizing C-200 and C22-3 vital antigen coated particles. J Pak Med Assoc. 1995;45:269–70.
19. Mohammad J, Hussain M, Khan MA. Frequency of hepatitis B and hepatitis C infection in thalassemic children. Pak Pediatr J. 2003;27:161–4.
20. Shah SAA, Khan MT, Ullah Z, et al. Prevalence of hepatitis B and hepatitis C virus infection in multitransfused thalassaemia major patients in northwest frontier province. Pak J Med Sci. 2005;21:281–4.
21. Hussain H, Iqbal R, Khan MH, et al. Prevalence of hepatitis C in beta thalassaemia major. Gomal J Med Sci. 2006;8:67–90.
22. Ali I, et al. Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa. Vitol J. 2012;28:296.
23. Sajid, M. frequency of hepatitis B and hepatitis C in multitransfused beta thalassaemia major patients in district Swat. J Saidu Med College 2013:3.
24. Khan MS, Ahmed M, Khan RA, et al. Consanguinity ratio in b-thalassemia major patients in district Bannu. J Pak Med Assoc. 2015;65:1161–3.
25. Shah T, Hussain W, Ali N, Sardar S, et al. Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study. Eur J Gastroen Hepat. 2019;31:248–52.
26. Younus M, Haasan K, Iqram N, et al. Hepatitis C virus seropositivity in repeatedly transfused thalassemia major patients. Int J Pathol. 2004;12:1020–3.
27. Iqbal BM, Hassan S, Azez S. Frequency of hepatitis B and hepatitis C in multi-transfused beta thalassaemia major patients. Pak Armed Forces Med J. 2010; 60(2):285–8.
28. Qurat-ul-Ain LA, Hassan M, Rana et al. Prevalence of β-thalassemic patients associated with consanguinity and anti-HCV-antibody positivity—a cross sectional study. Pak J Zool 2011;43(1):29–36.

29. Iqbal A, Farrukh H, Aslam S, et al. Frequency of hepatitis C in β-thalassemia major patients. Rawal Med J. 2013;38(4):328–31.

30. Din G, Malik S, Ali I, et al. Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med. 2014;7:5127–33.

31. Nazir S, Faraz A, Shahzad N, et al. Prevalence of HCV in β-thalassemia major patients visiting tertiary care hospitals in Lahore—Pakistan. Advancements Life Sci. 2014;14(1):197–201.

32. Saeed U, Waheed Y, Ashraf M et al. Estimation of hepatitis B virus, hepatitis C virus, and different clinical parameters in the thalassemic population of capital twin cities of Pakistan. Virology. 2015 Jan;6:VRT-S31744.

33. Ali SA, Donahue RM, Qureshi H, et al. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis. 2009 Jan 1;13(1):9–19.

34. Khan MR, Anwar S, Faizan ME, et al. The burden of transfusion related infections on thalassemia major children. Pak J Med Health Sci. 2017;11(3):882–6.

35. Shah SM, Khan MT, Ullah Z. Hepatitis-B and hepatitis-C virus infection in multi-transfused thalassemia major patients. Pak J Med Sci. 2005;21(3):281.

36. Raza T, Shabir A, Shumai A, et al. Frequency of hepatitis C virus infection in multi transfused patients of Beta thalassemia major at a tertiary Care Hospital in Lahore. Pak Pediatr J. 2018;42(2):165–9.

37. Mujeeb SA, Sheikh AA, Khanani R et al. Prevalence of hepatic C virus infection among β-thalassemia major patients. Trop Doct. 1997 Apr;27(2):105.

38. Akhtar S, Moatter T, Azam SI, et al. Prevalence and risk factors for intrafamilial transmission of hepatitis C virus in Karachi, Pakistan. J Viral Hepat. 2002;9(4):309–14.

39. Akhtar S, Moatter T. Intra-household clustering of hepatitis C virus infection in Karachi, Pakistan. Trans R Soc Trop Med Hyg. 2004;98(9):535–9.

40. Riaz H, Riaz T, Ullah F, et al. Assessment of the seroprevalence of viral hepatitis B, viral hepatitis C and HIV in multi-transfused thalassemia major patients in Karachi, Pakistan. Trop Doct. 2011;41(1):23–5.

41. Ansari SH, Shamsi TS, Khan MT, et al. Seropositivity of hepatitis C, hepatitis B and HIV in chronically transfused β-thalassaemia major patients. J Coll Physicians Surg Pak. 2012;22(9):610–1.

42. Sultan S, Siddiqui M, Zaidi SM. Current trends of seroprevalence of transfusion transmitted infections in Pakistani (Beta)-thalassaemic patients. Malays J Pathol. 2016;38(3):251.

43. Burki MF, Hassan M, Hussain H, et al. Prevalence of anti-hepatitis C antibodies in multiply transfused beta thalassemia major patients. Ann Pak Inst Med Sci. 2005;1(3):150–3.

44. Ahmed Khan R, Anwar M, Waheed U, et al. Epidemiology of transfusion transmitted infection among patients with β-thalassaemia major in Pakistan. J Blood Transfus. 2016.

45. Al Kanaani Z, Mahmud S, Koushounjjar S, Rizvi U. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci. 2018;5(4):180257.

46. Behzadi Faraj, Khorrami M, Rezegi M, et al. The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Arch Virol. 2018;163(5):1131–40.

47. Hossain B, Khan WA, Adhikari S, et al. Prevalence of hepatitis C virus infection in multi-transfused Thalassaemia patients in Bangladesh. J Enam Med Coll. 2018;8(1):16–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.